| Version 2.5.2.0 |
|
|
Abstract
Grant Number: 1R21AT002901-01A1 Project Title: Omega-3 Fish Oil for Nonalcoholic Steatohepatitis
PI Information: Name Title CALDWELL, STEPHEN H. shc5c@virginia.edu ASSOCIATE PROFESSOR Abstract: DESCRIPTION (provided by applicant): Nonalcoholic steatohepatitis (NASH) occurs in 2-3% of the US population and carries a 15-20% chance of progression to cirrhosis. It is closely associated with obesity, hyperlipidemia and insulin resistance. Therapy usually includes recommendations to increase exercise and to begin weight reducing diets but these goals are variably achieved and their relative effects in conjunction with pharmacological intervention have not been well-defined. Other forms of therapy include insulin sensitizing agents but no intervention is proven or uniformly accepted. Furthermore, interpretation of pharmacological treatment results is confounded by commonly recommended life-style changes voluntarily adopted by the patient. Polyunsaturated fatty acids, especially formulations rich in omega-3 fatty, are widely accepted and endorsed in the medical community for their beneficial effects on hyperlipidemia and coronary disease risk reduction. Recent data suggests that omega 3 fatty acids ameliorate hepatic steatosis in humans and in animal models of NASH by reducing hepatic fat content. We hypothesize that omega-3 fatty acid (3g/day) will produce improvement in NASH activity, liver fat content, and lipid profiles independent of weight loss or exercise conditioning compared to a placebo. Among commonly used supplements, omega-3 rich fish oils stand out as having won endorsement from the American Heart Association and FDA approval for a qualified health claim in coronary risk reduction. We have chosen a brand of omega-3 that exceeds purity marks set by European and Scandanavian Medicinal Standards and meets recently adopted criteria set by NCCAM. Our primary endpoint is to assess changes in a composite score of NASH-induced liver injury relative to changes in exercise tolerance and weight. Other secondary endpoints include changes in liver fat content by MRI, blood lipid profile, insulin sensitivity and markers of the metabolic syndrome after treatment. Statistical analysis will be performed to assess the impact of weight loss and changes in exercise tolerance on the primary endpoint relative to omega-3 use. This GCRC-based pilot study of 50 evaluable subjects will establish a workable platform for multicenter trials to measure the relative impact of voluntary life-style modification on potentially effective pharmacological therapy in treating NASH.
Public Health Relevance:
This Public Health Relevance is not available.Thesaurus Terms:
diet, exercise, fat, fatty acid, insulin sensitivity /resistance, marine animal oil, omega 3 fatty acid
exercise tolerance, human, injury, lifestyle, lipid, liver, measurement, reduction, weight loss
clinical research
Institution: UNIVERSITY OF VIRGINIA CHARLOTTESVILLE BOX 400195 CHARLOTTESVILLE, VA 229044195 Fiscal Year: 2006 Department: NONE Project Start: 01-SEP-2006 Project End: 31-AUG-2009 ICD: NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE IRG: ZAT1